Claudin-2 is a unique member of the claudin family of transmembrane proteins, as its expression is restricted to the leaky epithelium in vivo and correlates with epithelial leakiness in vitro. However, recent evidence suggests potential functions of claudin-2 that are relevant to neoplastic transformation and growth. In accordance, here we report, on the basis of analysis of mRNA and protein expression using a total of 309 patient samples that claudin-2 expression is significantly increased in colorectal cancer and correlates with cancer progression. We also report similar increases in claudin-2 expression in inflammatory bowel disease-associated colorectal cancer. Most importantly, we demonstrate that the increased claudin-2 expression in colorectal cancer is causally associated with tumor growth as forced claudin-2 expression in colon cancer cells that do not express claudin-2 resulted in significant increases in cell proliferation, anchorage-independent growth and tumor growth in vivo. We further show that the colonic microenvironment regulates claudin-2 expression in a manner dependent on signaling through the EGF receptor (EGFR), a key regulator of colon tumorigenesis. In addition, claudin-2 expression is specifically decreased in the colon of waved-2 mice, naturally deficient in EGFR activation. Furthermore, genetic silencing of claudin-2 expression in Caco-2, a colon cancer cell line, prevents the EGF-induced increase in cell proliferation. Taken together, these results uncover a novel role for claudin-2 in promoting colon cancer, potentially via EGFR transactivation.
Introduction
Tight junctions, (TJs) the most apical cell-cell adhesions, create a barrier for paracellular transport and help maintain epithelial cell polarity (Cereijido et al., 2004) . Pathological conditions, including cancers of epithelial origin, are associated with the loss of epithelial barrier function and polarity (Mullin, 2004) . The claudin family of proteins is integral to the TJ and contains 24 members that are expressed in a tissue-and/or cell-specific manner (Furuse and Tsukita, 2006) . Various diseases have been associated with structural and functional defects in claudin family members (Lal-Nag and Morin, 2009) . However, precise role of claudins in colonic epithelial cell function and pathological conditions remain largely unknown.
Among claudins, claudin-2 is unique as its expression is restricted to the leaky epithelia (Reyes et al., 2002; Escaffit et al., 2005) . In colon, claudin-2 expression is highest among the undifferentiated colonocytes at the crypt base and decreases with colonocyte differentiation (Escaffit et al., 2005; Holmes et al., 2006) . Notably, initial studies using limited patient samples have suggested that claudin-2 expression increases in colorectal cancer samples (Kinugasa et al., 2007) . However, a detailed analysis is warranted, especially in the light of recent reports that claudin-2 expression changes with the modulation of proliferation and migration (Guillemot and Citi, 2006; Takehara et al., 2009; Buchert et al., 2010) . Furthermore, it is important that we determine whether increased claudin-2 expression is causally associated with colorectal carcinogenesis, or is a simple bystander, and that we understand mechanism(s) underlying regulation of colonic claudin-2 expression. In the current study, we demonstrate that claudin-2 expression is significantly increased in colorectal cancer compared with the normal colon, and is causally associated with the colorectal cancer growth. We further show that EGF receptor (EGFR) tyrosine kinase activity helps maintain the endogenous colonic claudin-2 expression, and the colonic tissue microenvironment induces claudin-2 expression in an EGFR-dependent manner. Taken together, our current findings confirm a tumor-promoting role for claudin-2 in colon cancer, and implicate EGFRmediated signaling in these events.
Results
Claudin-2 expression is significantly upregulated in colorectal cancer To determine claudin-2 expression in colorectal cancer, we investigated expression levels between normal adjacent colon specimens (n ¼ 10) and patients with colorectal adenocarcinoma (n ¼ 250). We found that claudin-2 expression was significantly upregulated in the adenocarcinoma group for each stage compared with normal adjacent tissue specimens (Figure 1a , Po0.001 for all comparisons). These data suggest that claudin-2 is significantly upregulated in both early-and late-stage colorectal cancer tumors.
To determine a similar increase at the protein level, we examined claudin-2 expression in tissue lysates prepared from frozen, matched colon cancer and normal colon samples from nine patients. Immunoblot analysis showed an increase in claudin-2 expression in all tumor samples compared with their normal counterparts. Notably, expression of claudin-3, another claudin family member, remained largely unaltered in the same lysates (Figure 1b) .
We next performed immunohistochemical analysis using anti-claudin-2 antibody and tissue sections from 40 colorectal cancer patients. Mouse kidney was used as positive control in which claudin-2 immunoreactivity was found in TJs in the proximal tubules and thus validated the staining (data not shown). Intensity of claudin-2 staining was independently scored by a pathologist, and low and high scores were assigned (see Figure legend ). Claudin-2 expression was low in all normal colon cases, however, it increased in colorectal adenomas (72% low vs 28% high) and further increased in adenocarcinomas ; (23% low vs 77% high) (Table 1 and Supplementary Figure 1 ). w 2 -analysis of these data demonstrated a highly significant increase in claudin-2 levels in colorectal adenocarcinoma specimens compared with normal colon and adenomas (Po0.001). Taken together, our data show significantly increased claudin-2 expression in colorectal cancer and suggest the potential correlation of claudin-2 with cancer progression.
Claudin-2 expression is markedly increased in inflammatory bowel disease-associated cancer A robust increase in claudin-2 expression has emerged as a consistent feature of inflammatory bowel disease (IBD) (Heller et al., 2005; Ridyard et al., 2007; Zeissig et al., 2007) . Increased epithelial permeability characterizes IBD patients (D'Inca`et al., 1999) . IBD patients also have increased risk of developing colon cancer (Eaden et al., 2001) . Therefore, we examined the potential correlation of claudin-2 expression with IBDassociated cancer. Immunohistochemistry analysis showed that in the non-cancerous colitis tissues, C a n c e r C a n c e r C a n c e r C a n c e r C a n c e r C a n c e r C a n c e r C a n c e r C a n c e r (a) Normalized expression values for claudin-2 in normal adjacent colon specimens (n ¼ 10) compared with adenocarcinoma samples (n ¼ 250) from the Vanderbilt Medical Center and the Moffitt Cancer Center using microarray analysis. The demographics for this group are listed in Supplementary Table 1 . Claudin-2 was significantly increased in the adenocarcinoma group compared with the normal specimens (***Po0.001 for all comparisons). (b) Claudin-2 expression in colon cancer and adjacent normal colon samples. Total tissue lysates were prepared using frozen matched normal and cancer colon tissues from the same patient. b-Actin was used as loading control. The values on the left are molecular sizes in kilodaltons. Table 1 Claudin-2 immunolocalization in colonic mucosa and colon cancer
Claudin-2 staining Normal Adenoma Adenocarcinoma
Low claudin-2 ( þ 1 to þ 2) 13 10 0 High claudin-2 ( þ 3 to þ 5) 0 3 10
Claudin-2 immunoreactivity in human colon samples was scored by a pathologist in a blinded manner in which lowest and highest immunoreactivity were scored as þ 1 and þ 5, respectively, and represented a sum of membrane and cytoplasmic staining. Data has been presented as low ( þ 1 to þ 2) or high ( þ 3 to þ 5) expression for claudin-2. Claudin-2 staining was significantly higher in the adenocarcinoma group compared with the normal colon group (Po0.001, w 2 -test).
Claudin-2 and colon cancer P Dhawan et al claudin-2 staining was present at a low level in the surface colonocytes, in the apical cytoplasm and in TJs, and in the crypt epithelium, claudin-2 staining was punctate along the lateral membranes and was also present in the cytoplasm and 2B (i-ii)). Importantly, claudin-2 staining was highly increased in the cancers associated with Crohn's disease ( Supplementary Figure 2A ( iii-iv)) as well as ulcerative colitis (Supplementary Figure 2B (iii-iv)). This increased claudin-2 staining was present in lateral membranes, cytoplasmic granules, and/or was diffusely cytoplasmic.
Forced claudin-2 expression increases tumorigenicity of colon cancer cells On the basis of above data, we postulated a causal association of claudin-2 expression with colon cancer. In this regard, we first determined the expression profile of claudin-2 in a panel of colon cancer cell lines. As shown in Figure 2a , claudin-2 was expressed in majority of the cell lines tested. To further test a causal association, we forced expressed claudin-2 cDNA in SW480 and HCT116 colon cancer cells that did not exhibit detectable claudin-2 expression. Claudin-2 overexpressing cells were named SW480 Claudin-2 and HCT116 Claudin-2 . Immunoblot analysis confirmed robust claudin-2 overexpression in the selected polyclonal claudin-2 overexpressing population of both the cell types, whereas endogenous claudin-3, claudin-4, claudin-7 or claudin-15 expression remained largely unaltered. (Figures 2b (i) and c (i) and Supplementary Figure 3 ). Immunofluorescent analysis showed that the expressed claudin-2 was localized at the cell membrane and in the cytoplasm (Figures 2b (ii) and c (ii)).
To determine the effect of claudin-2 expression upon the tumorigenic ability of the respective cell lines we used anchorage-independent growth. As expected, SW480 and HCT116 control cells formed colonies in soft agarose. However, in both the cell types, forced claudin-2 expression resulted in significant increases in the number of colonies formed (Figures 2b (iii) and c (iii)). To further determine the effect of claudin-2 expression upon tumorigenesis in vivo, we injected SW480 Claudin-2 , HCT116 Claudin-2 and respective control cells (1 Â 10 6 cells) subcutaneously into the flanks of nude mice (n ¼ 7/group). Irrespective of the cell type injected, majority of the mice had measurable tumors within 1 week after inoculation (Figures 2b (iv) and c (iv)). However, tumor growth was faster in the mice injected with the claudin-2 overexpressing cells, and the average tumor volume was significantly higher in the mice injected with SW480 Claudin-2 or HCT116 Claudin-2 cells compared with those that received respective control cells (Po0.01 in both cases) after 5 weeks when the mice were killed (Figures 2b (iv) and c (iv)).
Claudin-2 overexpression increases proliferation and protects from the effects of 5-FU Forced claudin-2 expression significantly increased tumorigenicity of both cell types under study. As claudin-2 expression varies with changes in cell proliferation (Guillemot and Citi, 2006; Buchert et al., 2010) , we further determined the effects of claudin-2 overexpression upon cell proliferation using MTT assay. As shown in Figure 3 , we observed significant increases in cell proliferation in both HCT116 Claudin-2 and SW480 Claudin-2 cells compared with respective controls (Figures 3a and b; Po0.05) . Unchecked proliferation is central to tumorigenesis, including colon cancer, and is a key aspect of the resistance to the cancer treatment drugs. Therefore, we further examined the effects of fluorouracil (5-FU), a colon cancer treatment drug (Ansfield et al., 1977) , upon HCT116 Claudin-2 and control cells. Cells were exposed to progressively increasing concentrations of 5-FU and cell viability was determined at 24, 48 and 72 h after exposure to 5-FU. As expected, 5-FU decreased cell viability in a time-and dose-dependent manner, however HCT116 Claudin-2 cells were significantly (Po0.001 at 50 or 100 mM and Po0.01 at 200 mM) protected from the effects of 5-FU compared with the control cells ( Figure 3c ). We further determined specific contribution of proliferation vs apoptosis to the 5-FUdependent change in cell viability. As shown in Supplementary Figure 4 , 5-FU treatment inhibited proliferation (Po0.001), whereas increased apoptosis (Po0.05) in HCT116 control cells. However, HCT116 claudin-2 cells were largely resistant to the effects of 5-FU upon proliferation as well as apoptosis.
Coculture of colon cancer cells with colonic fibroblasts increases claudin-2 expression in an EGFR-dependent manner
In colon, a close association exists between the crypt epithelial cells and pericryptal fibroblasts. Emerging Z-sectioning confirmed that the expressed claudin-2 is localized at the apical cell membrane along with minor cytoplasmic distribution. Scale bar ¼ 10 mm. (b (iii)) Anchorage-independent growth. Po0.01 for SW480 Claudin-2 vs SW480 Control . (b (iv)) Flank tumor xenografts after subcutaneous injection of SW480 Control or SW480 Claudin-2 cells (n ¼ 7 mice/group). (*Po0.05 and **Po0.01, SW480 Claudin-2 group vs SW480 Control group, ANOVA). (c (i)) Claudin-2, claudin-4 or claudin-15 expression in HCT116 Control and HCT116 Claudin-2 cells. b-Actin was used for equal protein loading. The values on the left are molecular sizes in kilodaltons. (c (ii)) Confocal image analysis of immunoflourescent staining using anti-claudin-2 antibody. Z-sectioning demonstrated predominant membrane localization of the expressed claudin-2. Scale bar ¼ 10 mm. (c (iii)) Anchorage-independent growth. ***Po0.001 for HCT116 Claudin-2 vs HCT116 Control . (c (iv)) Flank tumor xenografts after subcutaneous injection of control HCT116 or HCT116 Claudin-2 cells (n ¼ 7 mice/group). (**Po0.01, HCT116 Claudin-2 group vs HCT116 Control group, analysis of variance).
Claudin-2 and colon cancer P Dhawan et al (Cutler et al., 2003) . As described, claudin-2 is, uniquely, compared with other colonic claudins, expressed in the crypt base (Holmes et al., 2006) . Therefore, we further determined the potential role of the tissue microenvironment in the regulation of colonic claudin-2 expression. In this regard, we performed coculture of colonic fibroblasts (Figure 4a ) with Caco-2 colon cancer cells that express endogenous claudin-2 protein. Effect of coculture upon claudin-2 and claudin-4 expression was examined. Coculture with either HCF-27 (normal pericryptal fibroblasts) or HNPCC (fibroblasts from hereditary nonpolyposis colorectal cancer individuals) (Cutler et al., 2003) cells had no appreciable effect upon claudin-4 expression; however, claudin-2 expression was significantly increased (Figure 4b ). This fibroblastdependent increase in claudin-2 expression was higher in cells cocultured with the HNPCC (Po0.001) compared with the HCF-27 (Po0.01) fibroblasts ( Figure 4b ). Importantly, this increase in claudin-2 expression was inhibited upon use of PD153035, an EGFR tyrosine kinase specific inhibitor ((Bos et al., 1997) ; Figure 4c ) or EGFR blocking antibody (Clone#528, 20 mg/ml; (Supplementary Figure 5) ). Together, our data supported the role of the colonic stroma in the regulation of claudin-2 expression in an EGFRdependent manner.
Exogenous EGF increases claudin-2 expression in colon cancer cells
The data from the coculture studies suggested a potential role of EGFR activation in the fibroblastdependent induction of claudin-2 expression in Caco-2 cells. This finding was in sharp contrast to our earlier report that in renal epithelial (MDCK-II) cells, EGFR activation decreases claudin-2 expression (Singh and Harris, 2004) . Therefore, we further determined the effect of the exogenous EGF upon claudin-2 expression in the colon-derived cells. Quiescent and polarized Caco-2 cells were exposed to EGF (100 ng/ml) and the effect upon TER, paracellular permeability and claudins expression was determined. Notably, EGF treatment resulted in a time-dependent and significant decrease in TER (Supplementary Figure 6A) , whereas paracellular permeability for FITC-dextran increased (Po0.001; Supplementary Figure 6B ). Furthermore, EGF treatment resulted in a marked increase in claudin-2 expression ( Figure 5a ; Po0.001), which was inhibited by PD153035. Notably, PD153035 alone inhibited the basal claudin-2 expression (Po0.05) in cells that did not receive EGF, suggesting that EGFR activation is required for the maintenance of baseline claudin-2 expression ( Figure 5a ). This EGF-dependent increase in claudin-2 expression was dose dependent (Figure 5b ) and was specific as expressions of claudin-3, claudin-4, claudin-8 and claudin-15 in EGF-treated Caco-2 cells was not different compared with the control Caco-2 cells (Figure 5a and Supplementary Figure 7 ) and involved regulation at the level of mRNA expression ( Figure 5c ; Po0.01). We further performed immunofluorescent analysis to examine the potential effects of EGFR activation upon cellular distribution of claudin-2 in colocalization with ZO-1. Confocal imaging showed predominant membrane distribution for ZO-1 in Caco-2 cells that remained largely unaltered in the EGF-treated cells (Figure 5d ). In contrast, claudin-2 staining was minimal in the untreated Caco-2 cells, but EGF stimulation markedly increased claudin-2 staining that was present along the cell membranes and cytoplasm in a granular pattern (Figure 5d ), and resembled claudin-2 staining in the colon cancer samples ( Supplementary  Figure 1) .
In further studies, we determined whether the contrasting effect of EGFR activation upon claudin-2 expression between MDCK-II and Caco-2 cells is due to differential transcriptional regulation. In this regard, we determined the effect of EGF stimulation upon human claudin-2 promoter activity in Caco-2 and MDCK-II cells as described in 'Materials and methods'. As shown in Figure 5e , EGF stimulation increased claudin-2 promoter activity in Caco-2 cells; however, it resulted in a sharp decrease in MDCK II cells, and thus suggested differential effects of EGFR activation upon claudin-2 transcriptional regulators between MDCK-II and Caco-2 cells.
We further determined whether the EGF-dependent increase in claudin-2 expression was a phenomenon common among colon cancer cells or limited only to the Caco-2 cells. We used HCT15 and HT-29 colon cancer cells that also express claudin-2 for this purpose. Similar to the Caco-2 cells, EGF treatment increased claudin-2 expression in HT-29 cells (Po0.001) that was prevented upon use of PD153035 (Figure 6a ). Induction of claudin-2 by EGF was also demonstrated in HCT15 cells (Figure 6b ; Po0.001). As in Caco-2 cells, EGF treatment had no appreciable effects upon claudin-4 expression in either HT-29 or HCT15 cells (Figures 6a  and b ).
ERK1/2 and PI-3 kinase mediate the EGF-dependent increase in claudin-2 expression We further determined signaling pathways downstream of EGFR activation that are important in the EGFdependent increase in claudin-2 expression. The key role(s) of ERK1/2 kinase, p-38 MAP kinase and/or PI-3 kinase, signaling pathways downstream of EGFR activation, in the regulation of EGFR-dependent cellular functions is established. We used pathwayspecific pharmacological inhibitors, in which cells were pretreated with either U0126 (10 mM; ERK1/2 kinase inhibitor), LY 294002 (20 mM; PI-3 kinase inhibitor) or SB202190 (5 mM; p-p38 kinase inhibitor) and control cells received vehicle (Dimethyl sulfoxide) for the same duration (Figure 6c ). The p-p38 MAP kinase inhibitor had no effect upon either baseline or EGFinduced claudin-2 expression, whereas the PI-3 kinase inhibitor partially inhibited the EGFR-dependent increase in claudin-2 expression (Po0.001, EGF þ LY294002 vs EGF treated). In contrast, the ERK 1/2 Claudin-2 and colon cancer P Dhawan et al kinase inhibitor inhibited the EGF-dependent increases in claudin-2 to the same extent as upon use of PD153035 (Figure 6c ; Po0.001, EGF þ PD153035 or EGF þ U0126 vs EGF treated, and Po0.05 EGF þ PD153035 or EGF þ U0126 vs control). Taken together, our data suggested the predominant role of the EGFR-ERK1/2 kinase axis in the regulation of colonic claudin-2 expression.
Colonic claudin-2 expression is decreased in waved-2 mice Our above data highlighted the importance of EGFR activation in the regulation of claudin-2 expression in colon-derived cell lines. Therefore, we examined whether similar correlation exists in vivo. We used waved-2 mice for this purpose where EGFR tyrosine kinase activity is naturally reduced by B95% (Luetteke et al., 1994) . Colon was collected from 8-to 10-week-old waved-2 and littermate wild-type (WT) mice. Immunoblot analysis using colon lysate showed robust claudin-3, claudin-7 and claudin-15 expressions, whereas claudin-1 expression was minimal. These expression patterns were well in accordance with the published reports (Holmes et al., 2006) , however, expressions were not much different between the WT and waved-2 mice colon. In contrast, claudin-2 expression was sharply decreased in the waved-2 mice colon compared with the WT mice colon (Figures 7a and b) . These findings were supported by further co-immunofluorescent analysis, which showed intense membrane localized claudin-3 expression in the WT and waved-2 mice colon that extended from the base to the tip of the colonic crypts. In contrast, claudin-2 expression was localized to the crypt base in the WT mice colon, as previously described (Holmes et al., 2006) and was sharply decreased in waved-2 mice colon (Figure 7c ). Taken together, our data showed that the EGFRtyrosine kinase activity helps maintain colonic claudin-2 expression.
Genetic silencing of claudin-2 expression prevents EGF-induced proliferation We observed significant increase in cell proliferation upon expression of claudin-2 in colon cancer cells deficient in endogenous claudin-2 expression ( Figures  3a and b) . Therefore, in light of our findings that exogenous EGF increased claudin-2 expression in colon cells, we further examined the effect of EGF treatment upon cell proliferation in correlation with claudin-2 expression. Proliferation was determined in exponentially growing Caco-2 cells in the presence or absence of exogenous EGF (100 ng/ml), and significant increases in cell proliferation were observed with EGF addition (Figure 7d (i), Po0.001). To examine the association between EGF-induced claudin-2 expression and proliferation, we either silenced claudin-2 expression in Caco-2 cells (Caco-2 Cl-2KD cells) or stably overexpressed (Caco-2 Claudin-2 cells) (Figures 7d (iii) and (ii), respectively). Further studies showed significant increase in proliferation in exponentially growing Caco-2 Claudin-2 cells (Po0.01) and a decrease in Caco-2 Cl-2KD cells (Po0.001) compared with the Caco-2 Control cells (Figure 7d (iv) ), which supported our findings from SW480 and HCT116 cells (Figure 3) . Importantly, further studies in which Caco-2 Claudin-2 and Caco-2 Cl-2KD cells were exposed to exogenous EGF (100 ng/ml) showed that claudin-2 overexpression did not affect the EGF-induced proliferation; however, silencing of claudin-2 expression prevented the EGF-induced proliferation in Caco-2 cells (Figure 7d (iv) ). Cell viability was determined at 24, 48 and 72 h after exposure to 5-FU. Data representative of 24, 48 and 72 h after 5-FU treatment, however, shown only after 48 h. The dose of 5-FU to kill 50% of cells (LD 50 ) was 160 mM for HCT116 Claudin-2 cells compared with 70 mM for HCT116 Control cells when exposed for the same duration (**Po0.01 and ***Po0.001, analysis of variance).
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Discussion
In this study, we have confirmed and conclusively demonstrated, using an extensive database of human colon cancer samples and performing mRNA and protein expression quantification, that claudin-2 expression is significantly increased in colorectal cancer and correlates with tumor progression. Most importantly, we have demonstrated that the increased claudin-2 expression is causally associated with colorectal cancer as forced claudin-2 expression increased the tumorigenic ability of colon cancer cells. We have further demonstrated that the colonic tissue microenvironment potentiates the induction of claudin-2 expression in an EGFR-dependent manner and colonic claudin-2 expression is specifically decreased in waved-2 mice. Importantly, EGFR signaling is a key regulator of colorectal carcinogenesis. Furthermore, in waved-2 mice, normal proliferative response is blunted following partial small bowel resection (Helmrath et al., 1998) , and presence of waved-2 allele reduces intestinal polyps by B90% in the APC min mouse model (Roberts et al., 2002) . In addition, symplekin, a transcription cofactor and colon tumor promoter, increases claudin-2 expression in colon cancer cells (Buchert et al., 2010) , whereas matriptase, a putative colon tumor suppressor, decreases claudin-2 expression (Buzza et al., 2010) . Furthermore, nonsteroidal anti-inflammatory drug-dependent inhibition of cell invasion in colon cancer cells can be reversed by claudin-2 expression (Mima et al., 2008) . In accordance, in our studies, claudin-2 overexpression protected HCT116 cells from the cytotoxic effects of 5-FU. Claudin-2 is a TJ integral protein that converts TJ from a tight to a leaky strand phenotype (Furuse et al., 2001; . In transformed epithelia, evidence of increased TJ permeability has been demonstrated, and in colon adenocarcinomas, epithelial permeability was higher compared with the adjacent (Cutler et al., 2003) and normal colonic pericryptal fibroblasts HCF-27 on claudin-2 and claudin-4 expression; (b (ii)) Representative densitometric analysis (**Po0.01 and ***Po0.001 coculture vs control, t-test). (c (i)) Caco-2 cells were cocultured with the colonic fibroblasts in the presence and/or absence of the EGFR inhibitor, PD 153035; (c (ii)) Representative densitometric analysis (mean±s.e.m.; *Po0.05, **Po0.01 and ***Po0.001 coculture þ PD153035 vs coculture, t-test).
Claudin-2 and colon cancer P Dhawan et al normal colon (Soler et al., 1999) . Further, transepithelial impedance decreases across the colons of mice treated with chemical carcinogens (Davies et al., 1989) . These findings lead to the speculation that claudin-2 expression may underlie the increased permeability in colon cancer. This concept gains support from the documented increase in claudin-2 expression as well as colonic epithelial permeability in IBD patients (Heller et al., 2005; Prasad et al., 2005; Amasheh et al., 2009) . Notably, IBD patients are at an increased risk of developing colon cancer (Eaden et al., 2001 ). In the current study, we have observed increased claudin-2 Confocal imaging showed that the intensity or membrane localization of ZO-1 was largely unaltered by EGF treatment, whereas claudin-2 staining was markedly increased and was localized at the membrane and in the cytoplasm. Scale bar ¼ 10 mm. (e) Luciferase reporter assay. Caco-2 and MDCK-II cells were transiently transfected with a luciferase reporter construct containing human (1.2 kb) claudin-2 promoter or empty PGL-3 vector. At 24 h posttransfection cells were serum starved (overnight) and then exposed to EGF (100 ng/ml). At 18 h after EGF treatment, samples were collected and processed. Firefly luciferase activity was normalized to Rotylenchulus reniformis luciferase activity (co-transfected reference plasmid) and plotted as mean ± s.e.m.
Claudin-2 and colon cancer P Dhawan et al expression in IBD-associated cancer. Our findings are in accordance with the finding of a recent study that reported a potential correlation of claudin-2 expression with IBD-associated neoplastic transformation (Weber et al., 2008) . In this regard, we found that EGF-induced claudin-2 expression was paralleled by an increase in paracellular permeability and a decrease in TER. An association between the tumor promoter-induced TJ permeability (Mullin and O'Brien, 1986) , transepithelial flux of growth factors (Mullin and McGinn, 1987) and development of epithelial tumors (Mullin et al., 1992) has been shown by studies utilizing in vitro models of epithelial neoplasia. Thus, an increase in claudin-2 expression would render the colonic epithelium permeable and in turn luminal carcinogenic agents, including luminal growth factors such as EGF, would gain access Figure 6 EGF induced increase in claudin-2 expression was not limited to Caco-2 cells and was mediated through MAP ERK 1/2 and PI-3 kinase. (a) Quiescent HT-29 cells were exposed to exogenous EGF (100 ng/ml), PD153035 (0.5 mM) or both. Effect on expression of claudin-2 and claudin-4 was determined. b-Actin was used as loading control (***Po0.001 EGF treated vs control and $$$ Po0.001 EGF treated vs EGF þ PD153035). (b) Quiescent HCT15 cells were exposed to EGF as above and effect upon claudin-2, claudin-4 and b-actin was examined (***Po0.001 EGF treated vs control). (c (i)) Quiescent Caco-2 cells were exposed to EGF alone or in combination with PD153035 (0.5 mM), U0126 (10 mM), SB203580 (5 mM) or LY294002 (20 mm). The effect upon claudin-2 and claudin-4 expressions was determined. b-Actin was used as loading control. (c (ii)) Representative densitometric analysis (*Po0.05 vs control; ***Po0.001 vs control and $$$ Po0.001 vs EGF). The values on the left are molecular sizes in kilodaltons. to their receptor located basolaterally, and thus induce unregulated proliferation and potentially neoplastic transformation/growth. A similar hypothesis can be postulated for IBD-associated cancer in which increased colonic epithelial permeability due to increased claudin-2 expression results in increased access of immunogenic substances, normally present in the lumen, to the mucosa and thereby initiate immune responses. In turn, cytokines (such as, tumor necrosis factor-a) further increase claudin-2 expression (Mankertz et al., 2009) , and thus initiate a vicious cycle leading to chronic inflammation and thus increased susceptibility to colon cancer. Further investigations are needed to corroborate such postulations and are currently underway in our laboratory.
Colonic claudin-2 expression is uniquely restricted to the crypt base, which is the proliferative zone (Escaffit et al., 2005; Holmes et al., 2006) . Claudin-2 has also been identified as a target of Wnt/b-catenin signaling (Mankertz et al., 2004) . Thus, potential role(s) of claudin-2 in cellular functions other than the known effects on TJ function can be suggested. In our studies, forced claudin-2 expression in colon cancer cells increased proliferation and anchorage-independent growth. Our findings gain support from the report that silencing of claudin-2 expression in HT-29 colon cells decreased cyclin-D expression (Buchert et al., 2010) . Also, increased proliferation upon knockdown of cingulin was associated with an increase in claudin-2 expression (Guillemot and Citi, 2006) . Taken together, a direct/indirect role of claudin-2 in the regulation of colonocyte proliferation is postulated.
This hypothesis gains strength from our finding that EGFR activation not only induced colonic claudin-2 expression but also appeared necessary to maintain the endogenous colonic claudin-2 expression. This EGFdependent induction of claudin-2 in colon cancer cells is in contrast to our previously published report using renal epithelial cells, MDCK-II, in which EGFR activation resulted in a sharp decrease in claudin-2 expression (Singh and Harris, 2004) . Other groups, since then, have reported similar effects of EGFR activation upon claudin-2 expression in MDCK-II cells (Angelow et al., 2007; Flores-Benitez et al., 2007) . Our current studies using human claudin-2 promoter suggest that the differential effects of EGFR activation upon claudin-2 transcriptional regulators may underlie the contrasting effect of EGF stimulation on claudin-2 expression among renal and colonic epithelial cells. Currently, we are in the process of identifying putative transcription factors involved in this differential regulation. Notably, EGFR activation also increases claudin-2 expression in lung cancer cells (Peter et al., 2009) , and thus supports tissue specificity of such regulation and highlights the importance of the tissue microenvironment. Similar tissue specificity for claudin-2 regulation is reported for hepatocyte nuclear factor as this is required for claudin-2 expression in liver but not in the kidney (Sakaguchi et al., 2002) .
Further, the EGF-induced increase in claudin-2 expression in Caco-2 cells was paralleled by a significant increase in cell proliferation and silencing of claudin-2 expression abolished this EGF-induced increase in proliferation. EGFR kinase activation promotes intestinal epithelial cell proliferation and crypt size (Dahlhoff et al., 2008) . EGFR has an important role in the regulation of intestinal tumorigenesis (Roberts et al., 2002) . In colon cancer patients, EGFR activation is correlated with poor prognosis and increased mortality (Rego et al., 2009) . The proliferative and survival roles of EGFR are commonly mediated through the activation of ERK1/2 and/or PI-3 kinase signaling pathways. Also, activation of these pathways has been associated with the growth/progression of colon cancer. In our studies, the EGF-dependent increase in claudin-2 was abolished completely upon inhibition of ERK1/2 signaling and partially upon inhibition of PI-3 kinase. Taken together, our data strongly supports a correlation between claudin-2 expression and colonocyte proliferation and/or survival. Our findings gain support from other published findings that have shown similar dependence of claudin-2 expression upon ERK1/2 or PI-3 kinase signaling in colon-derived cell lines (Kinugasa et al., 2000; Prasad et al., 2005) .
Our finding that coculture of colon cancer cells with colonic fibroblasts increases claudin-2 expression in an EGFR-dependent manner further supports the role of claudin-2 in the regulation of colon cancer, potentially through EGFR activation. Notably, a DSS colitisinduced decrease in colonic claudin-2 expression was reverted in response to mesenchymal stem cells (Yabana et al., 2009) . The role of the tissue microenvironment, including fibroblasts, has emerged as an important aspect of the regulation of tumorigenesis. However, the detailed mechanism(s) underlying the fibroblastdependent activation of EGFR remains unclear at present, although our data does exclude the direct role of EGF (data not shown). In this regard, a potential candidate is prostaglandin E 2 , which is abundantly synthesized by colonic fibroblasts (Zhu et al., 2003) and activates EGFR in colon cancer cells (Pai et al., 2002) . Tumor necrosis factor-a, a known inducer of colonic claudin-2 expression (Mankertz et al., 2009) , stimulates prostaglandin E 2 synthesis (Kim et al., 1998) and activates EGFR in colon cancer cells (Yamaoka et al., 2008) . However, EGFR can also be activated by other mechanism(s) including the activation of G-protein coupled receptors (Singh and Harris, 2005) . Currently, we are in the process of examining the details of fibroblast-dependent activation of EGFR activation and claudin-2 expression.
Overall, in the current study, we have demonstrated a consistent and significant increase in claudin-2 expression in colon cancer and a causal association between claudin-2 and colon carcinogenesis. Importantly, we show that colonic claudin-2 expression is upregulated by the tissue microenvironment in an EGFR-dependent manner. Our findings will provide a new understanding of the molecular details of colon cancer regulation, specifically in the context of EGFR signaling. Our findings may also help understand the correlation between epithelial permeability, neoplastic transforma-tion and colon cancer. In addition, we provide new data regarding the potential role of claudin-2 in the regulation of colonocyte proliferation and survival. Our findings may prove to have important clinical implications, considering the known roles of EGFR and epithelial permeability in the regulation of colon cancer, as our identification of claudin-2 as an important link between EGFR and alterations in colonocyte function suggest that it could be a target for therapeutic intervention.
Materials and methods

Plasmids and reagents
A pcDNA-4 expression plasmid (Invitrogen Inc., Carlsbad, CA, USA) containing the claudin-2 coding sequence was used for overexpression. Human claudin-2-specific and control small-hairpin RNA constructs were obtained from Sigma-Aldrich (St Louis, MO, USA). Antibodies against claudin-1, -2, -3, -4, -7, -15 and ZO-1 were obtained from Invitrogen. EGF, PD 153035, U0126, SB-239063 and LY-294002 were from EMD Biosciences (Gibbstown, NJ, USA).
Cell culture and transfection
The source and culture conditions of the cell lines used have been previously described (Dhawan et al., 2005) . Claudin-2 overexpressing cell population was selected using Zeocin (0.4 mg/ml). For coculture, fibroblasts were plated on the bottom surface of transwell filters (0.4 mm pore size). Caco-2 cells were plated on the filter top once fibroblasts were attached (Figure 4a ).
Human tissue, microarray platforms and statistical analysis
The protocols and procedures for the procurement of human tissue samples, details of the microarray platforms and statistical analysis have been described previously (Krishnan et al., 2010) .
Immunoblot, immunohistochemistry and immunofluorescence analyses These analyses were performed as previously described (Dhawan et al., 2005) .
MTT assay
The CellTiter assay (MTT assay; Promega Inc.) was conducted as described previously (Dhawan et al., 2005) .
Anchorage-independent growth assay
This anchorage-independent growth assay was conducted as described previously (Dhawan et al., 2005) . Colonies were counted using Gel Count (Bio-Rad).
In vivo studies All animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee at Vanderbilt University. Subcutaneous flank inoculation of claudin-2 overexpressing or control cells was performed in 6-week-old athymic mice. Tumor incidence, tumor growth and animal conditions were assessed on a continuous basis for 5 weeks after inoculation, at which time animals were killed.
Luciferase reporter assay
This assay was carried out using a human claudin-2 (1.2 kb) promoter (Sakaguchi et al., 2002) construct containing firefly luciferase reporter as described previously (Shiou et al., 2007) .
Statistical analysis
Student's t-test, w 2 -test and analysis of variance were used to determine statistical significance as applicable, and differences were considered statistically significant at Po0.05.
